Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo Ford, Janet Dunn, Andrea Marshall et al.|The Lancet Oncology|2013Cited by 604
Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working PartyBradley Augustson, Mark T. Drayson, Gulnaz Begum et al.|Journal of Clinical Oncology|2005Cited by 489
(untitled)Christina Yau, Adam L. Asare, Marie Osdoit et al.|Edinburgh Research Explorer|0Cited by 353
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trialMark T. Drayson, Janet Dunn, Stella Bowcock et al.|The Lancet Oncology|2019Cited by 160
The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognosesHelen Campbell, Mark Sculpher, David Epstein et al.|European Journal of Cancer|2011Cited by 46